In this study, we demonstrate that the concomitant status of EGFR and p53 is a key determinant of patient outcomes; survival was shorter in patients with EGFR-immunopositive astrocytomas with low p53 expression levels. This evidence concerns the gene EGFR and astrocytoma (excluding glioblastoma).